June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Exploration of the phenomenon of regression to the mean in visual acuity measurements in patients with age-related macular degeneration
Author Affiliations & Notes
  • Simona Degli Esposti
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Omar Abdul Rahman Mahroo
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Praveen J Patel
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Adnan Tufail
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships   Simona Degli Esposti, Novartis (R); Omar Mahroo, None; Praveen Patel, Bayer (C), Genentech Inc (C), Heidelberg Inc (F), Merck Inc (C), Novartis (C), Roche UK (C), Salutaris MD (R), Thrombogenics NV (C), Thrombogenics NV (F), Topcon Inc (F); Adnan Tufail, Allergan (C), Bayer (C), GSK (C), Novartis (C), Pfizer (C), Thrombogenics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4696. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Simona Degli Esposti, Omar Abdul Rahman Mahroo, Praveen J Patel, Adnan Tufail; Exploration of the phenomenon of regression to the mean in visual acuity measurements in patients with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4696.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In clinical trials and real-world data, gains in visual acuity are frequently highest in those with lowest baseline acuity. Some of this effect may relate to the phenomenon of regression to the mean. We explored this by analysing visual acuity measurements made on two occasions in untreated eyes, and assessing change in visual acuity for those with the highest and lowest acuities.

Methods : Best-corrected ETDRS visual acuity recorded at baseline (“visit 1”) and week 1 (“visit 2”) from the untreated fellow eyes of participants in the ABC trial (Bevacizumab for neovascular age related macular degeneration; Tufail et al., BMJ, 2010) were analysed. Participants seeing fewer than 5 letters on either occasion were excluded. Those in the top and bottom 10% at visit 1 were identified, and the means compared between visits (visit 2 minus visit 1). The top and bottom 10% at visit 2 were also identified, and their means compared between visits (visit 1 minus visit 2).

Results : Ninety-nine patients were included. Mean (SD) age was 78.5 (6.9) years. Mean (SD) acuities were 63.7 (24.7) and 65.0 (25.1) for visits 1 and 2 respectively. For the top 10% at visit 1, the mean visual acuity changed by 0 letters between visits 1 and 2. For the bottom 10% at visit 1, mean visual acuity changed by +3.5 letters (p=0.14) by visit 2. When comparing backwards, for the top 10% at visit 2, the mean visual acuity changed by -1.25 letters (p=0.015), i.e. the mean for visit 1 was lower. For the bottom 10% at visit 2, the mean visual acuity changed by +4.4 letters (p=0.16), i.e. the mean for visit 1 was greater.

Conclusions : In this exploratory study, effects consistent with regression to the mean were observed. When eyes with the lowest 10% of visual acuities were identified at either visit, they appeared to improve their vision at the other visit irrespective of whether this was forwards or backwards in time. The effect appeared smaller/absent for the top 10%, which may be due to the lower variability in acuity measurements in this group. The regression to mean effect is greater the more the variability in the measurement.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×